and surgical risk because the control group comprised patients for whom sutureless AVR was not indicated. Santarpino et al Perceval S SSAS 18.1 81.5 Mini all First enrolled Perceval S patients were part of the CAVALIER (2013)() (n = 37) sutureless AVR multicentre trial; later patients received Perceval S under routine use Age ≥65y Disclosure: Financial relationship with Sorin disclosed by two of the TAVI 20.6 84.5 authors (Pfeiffer and Fischlein) (n = 37) Design: retrospective. Propensity matched. Shrestha et al Perceval S Age 20.4 80 Mini 72% Perceval group may be part of Perceval Pivotal trial and/or ≥75y (2013)() (n = 50) CAVALIER Small aortic roots Isolated AVR (<22mm) Unclear whether control group were ineligible for Perceval S or were treated prior to Perceval S being in use Standard 16.7 77 Mini 4% Unclear whether data on control patients were collected prospectively AVR Isolated AVR Disclosure: Institute received an unrestricted research grant from (n = 70) Sorin to conduct the study Design: Prospective. Baseline characteristics did not differ significantly between groups other than a marginally higher surgical risk in the Perceval S group (20.4 vs 16.7; p = 0.05) Doss et al 3f Enable Severe AS 13.7 78 Full sternotomy Unclear how patients were selected for treatment group (2012)() and concomitant (n = 27) 3f Enable patients may be part of larger study as reported in Martens procedures 37% et al. 2011() Partial Reports initial experience with the technologies at the study centre sternotomy for No information provided regarding funding and conflicts of interest isolated AVRs Design: Prospective, nonrandomised cohorts. Surgical risk TAVI 35.3 85 Transapical TAVI significantly higher in the TAVI group (n = 29) Design: Prospective, nonrandomised cohorts Muneretto et al Perceval S Severe AS 16 79 18.9% (2014)() ministernotomy (n=53) CoreValve 20.4 81 Transfemoral TAVI (n=55)
and surgical risk because the control group comprised patients for whom sutureless AVR was not indicated. Santarpino et al (2013)() Perceval S (n = 37) SSAS Age ≥65y 18.1 81.5 Mini all sutureless AVR First enrolled Perceval S patients were part of the CAVALIER multicentre trial; later patients received Perceval S under routine use Disclosure: Financial relationship with Sorin disclosed by two of the authors (Pfeiffer and Fischlein) Design: retrospective. Propensity matched. TAVI (n = 37) 20.6 84.5 Shrestha et al (2013)() Perceval S (n = 50) Age ≥75y Small aortic roots (<22mm) 20.4 80 Mini 72% Isolated AVR Perceval group may be part of Perceval Pivotal trial and/or CAVALIER Unclear whether control group were ineligible for Perceval S or were treated prior to Perceval S being in use Unclear whether data on control patients were collected prospectively Disclosure: Institute received an unrestricted research grant from Sorin to conduct the study Design: Prospective. Baseline characteristics did not differ significantly between groups other than a marginally higher surgical risk in the Perceval S group (20.4 vs 16.7; p = 0.05) Standard AVR (n = 70) 16.7 77 Mini 4% Isolated AVR Doss et al (2012)() 3f Enable (n = 27) Severe AS 13.7 78 Full sternotomy and concomitant procedures 37% Partial sternotomy for isolated AVRs Unclear how patients were selected for treatment group 3f Enable patients may be part of larger study as reported in Martens et al. 2011() Reports initial experience with the technologies at the study centre No information provided regarding funding and conflicts of interest Design: Prospective, nonrandomised cohorts. Surgical risk significantly higher in the TAVI group TAVI (n = 29) 35.3 85 Transapical TAVI Muneretto et al (2014)() Perceval S (n=53) Severe AS 16 79 18.9% ministernotomy Design: Prospective, nonrandomised cohorts CoreValve TAVI (n=55) 20.4 81 Transfemoral
sutureless-aortic-valve-replacement-tier3-assessment.docx